118 related articles for article (PubMed ID: 38280407)
1. HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition.
Wang S; Cheng H; Huang Y; Li M; Gao D; Chen H; Su R; Guo K
Biochim Biophys Acta Mol Cell Res; 2024 Mar; 1871(3):119680. PubMed ID: 38280407
[TBL] [Abstract][Full Text] [Related]
2. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
3. PBK/TOPK promotes chemoresistance to oxaliplatin in hepatocellular carcinoma cells by regulating PTEN.
Cao H; Yang M; Yang Y; Fang J; Cui Y
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):584-592. PubMed ID: 33772548
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy.
Ren WW; Li DD; Chen X; Li XL; He YP; Guo LH; Liu LN; Sun LP; Zhang XP
Cell Death Dis; 2018 May; 9(5):547. PubMed ID: 29749374
[TBL] [Abstract][Full Text] [Related]
5. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer.
Shi Y; Niu Y; Yuan Y; Li K; Zhong C; Qiu Z; Li K; Lin Z; Yang Z; Zuo D; Qiu J; He W; Wang C; Liao Y; Wang G; Yuan Y; Li B
Nat Commun; 2023 Apr; 14(1):1932. PubMed ID: 37024475
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of GFRα1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy.
Zhu H; Huang M; Luo J; Ji X; Liu Q
Pharmacol Res; 2021 Oct; 172():105815. PubMed ID: 34391932
[TBL] [Abstract][Full Text] [Related]
7. The HN1/HMGB1 axis promotes the proliferation and metastasis of hepatocellular carcinoma and attenuates the chemosensitivity to oxaliplatin.
Wang R; Fu Y; Yao M; Cui X; Zhao Y; Lu X; Li Y; Lin Y; He S
FEBS J; 2022 Oct; 289(20):6400-6419. PubMed ID: 35596723
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Que KT; Zhou Y; You Y; Zhang Z; Zhao XP; Gong JP; Liu ZJ
J Exp Clin Cancer Res; 2018 Nov; 37(1):268. PubMed ID: 30400960
[TBL] [Abstract][Full Text] [Related]
10. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
11. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
12. Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma.
Liao X; Bu Y; Chang F; Jia F; Song G; Xiao X; Zhang M; Ning P; Jia Q
BMC Cancer; 2019 Dec; 19(1):1192. PubMed ID: 31805888
[TBL] [Abstract][Full Text] [Related]
13. LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro.
Chen J; Yuan D; Hao Q; Zhu D; Chen Z
Adv Clin Exp Med; 2021 Aug; 30(8):831-838. PubMed ID: 34286514
[TBL] [Abstract][Full Text] [Related]
14. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
Lu J; Xu L; Zou Y; Yang RX; Fan Y; Zhang W; Yu D; Yao YG
Med Sci Monit; 2014 Feb; 20():247-54. PubMed ID: 24531386
[TBL] [Abstract][Full Text] [Related]
15. Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.
Cui Z; Li C; Liu W; Sun M; Deng S; Cao J; Yang H; Chen P
Cell Death Dis; 2024 Apr; 15(4):267. PubMed ID: 38622131
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.
Zhang F; Hu K; Liu W; Quan B; Li M; Lu S; Chen R; Ren Z; Yin X
Cell Mol Gastroenterol Hepatol; 2023; 15(3):573-591. PubMed ID: 36513250
[TBL] [Abstract][Full Text] [Related]
17. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.
Yin X; Zheng SS; Zhang L; Xie XY; Wang Y; Zhang BH; Wu W; Qiu S; Ren ZG
Gene; 2017 Jan; 596():53-88. PubMed ID: 27729273
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.
Huang H; Chen J; Ding CM; Jin X; Jia ZM; Peng J
J Cell Mol Med; 2018 Jun; 22(6):3238-3245. PubMed ID: 29602203
[TBL] [Abstract][Full Text] [Related]
19. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract][Full Text] [Related]
20. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
